Insider Transactions in Q2 2023 at Syros Pharmaceuticals, Inc. (SYRS)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 01
2023
|
Marsha Fanucci |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Andrew M. Oh |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Timothy Tyson |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+12.05%
|
-
|
|
Jun 01
2023
|
Peter Wirth |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Jun 01
2023
|
Richard A Young |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+9.96%
|
-
|
|
Jun 01
2023
|
Sue Gail Eckhardt |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+25.0%
|
-
|
|
Apr 03
2023
|
Eric R Olson Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-7.81%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-12.24%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-7.82%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
658
-32.9%
|
$1,316
$2.58 P/Share
|
|
Apr 03
2023
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
623
-31.15%
|
$1,246
$2.58 P/Share
|
|
Apr 03
2023
|
Nancy A Simonian |
SELL
Payment of exercise price or tax liability
|
Direct |
1,852
-2.46%
|
$3,704
$2.58 P/Share
|